Single-Dose Basiliximab Induction in Low-Risk Renal Transplant Recipients.
To compare the efficacy of a single dose of basiliximab with two doses in preventing acute rejection in selected low-risk renal transplant recipients.



This observational study of 760 kidney transplant recipients considered to be at low immunologic risk (peak panel reactive antibody less than 10%) compared patient and graft outcomes following a single-dose versus a two-dose regimen of basiliximab.



No differences were found in patient survival (92% vs 92%, p=0.6), graft survival (86% vs 83%, p=0.2), acute rejection (cellular [4% vs 7%, p=0.2], antibody-mediated rejection [19% vs 19%, p=0.9]), or opportunistic infections (34% vs 30%, p=0.3) between the single versus two-dose regimens, respectively. In multivariate analyses, the number of doses of basiliximab was not associated with acute rejection or patient/graft survival despite adjustment with Cox regression and propensity scores. However, delayed graft function (DGF), donor age older than 65 years, and human leukocyte antigen mismatch of 3 or higher were associated with acute rejection (hazard ratio [HR] 2.64, 1.91, and 1.57, respectively, p≤0.04), and DGF and diabetes were associated with death/graft loss (HR 2.56 and 1.63, respectively, p≤0.009).



A single dose of basiliximab is safe and effective for induction in low-risk kidney transplant recipients.
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois.
Kathleen C
KC
Cunningham
Department of Pharmacy, University of Wisconsin, Madison, Wisconsin.
David R
DR
Hager
Department of Pharmacy, University of Wisconsin, Madison, Wisconsin.
Jessica
J
Fischer
Department of Surgery, University of Wisconsin, Madison, Wisconsin.
Anthony M
AM
D'Alessandro
Department of Surgery, University of Wisconsin, Madison, Wisconsin.
Glen E
GE
Leverson
Department of Surgery, University of Wisconsin, Madison, Wisconsin.
Dixon B
DB
Kaufman
Department of Medicine, University of Wisconsin, Madison, Wisconsin.
Arjang
A
Djamali
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D051799:Delayed Graft Function / Q000209:etiology; D005260:Female; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab
basiliximab; graft loss; induction; kidney transplantation; patient death; rejection